report cf franchis revenu vs consensu non-gaap
ep vs consensu reiter guidanc result ph
trial tripl track data falcon trial confirm
lead tripl competit expect industry-lead top-
line growth thru remain top pick
vertex report cystic fibrosi cf franchis revenu q/q
y/i ahead consensu estim though
revenu includ kalydeco sale q/q y/i orkambi
q/q y/i symdeko revenu q/q oper expens
yield non-gaap oper margin
non-gaap ep ahead consensu vertex reiter
guidanc includ total cf product revenu combin non-
 sg total revenu estim remain
non-gaap ep estim increas tonight call
suggest time reimburs franc uk remain uncertain
remov assumpt revenu either countri model
reduc total revenu estim non-gaap ep
estim
vertex phase program consist trial tez/iva /-
homozygot tez/iva vs placebo het min patient tez/iva
vs placebo het min patient tez/iva /-
homozygot trial complet enrol top-lin data expect
late trial expect complet enrol produc
data nda submiss slate approv anticip
think phase ii data larg de-risk phase trial
moreov sens investor anticip produc percentag point
placebo-adjust increas het min trial dose
produc greater percentag point improv het min patient
phase ii efficaci endpoint ph timpoint week think
investor expect like met
last night glpg/abbv provid updat cf program falcon trial
doublet increas sweat chlorid mmol/l
subsequ two week treatment tripl regimen
increas sweat chlorid tripl improv
sweat chlorid initi glpg/abbv combin appear
competit glpg/ also announc would assum world-wide right
compound previous develop collabor mileston payment
well potenti add mileston royalti caus investor worri
may redoubl effort howev price paid rel modest
clear would advanc tripl late stage test
clearli competit lead tripl fall well short seemingli need
better potenti corrector remain skeptic program threat
pleas see page report import disclosur
cftr potenti kalydeco standard care cf patient gate partial loss
function mutat also develop regimen contain kalydeco cftr
corrector lumacaftor tezacaftor potenti address cf patient
harbor least one allel orkambi lumacaftor kalydeco approv
juli symdeko tezacaftor kalydeco februari tripl combin
contain gener corrector well tezacaftor ivacaftor produc impress
ph ii data regimen enter pivot develop fda file
anticip tripl regimen appear repres true breakthrough
treatment improv qualiti life extend life span patient
model assum cystic fibrosi patient one vertex therapi
drive franchis sale dcf-base price target
initi data ph trial tez/iva
complet enrol ph trial
eu approv symkevi
cystic fibrosi patient
one vertex therapi
drive franchis sale
franchis maintain exclus
earli
rest pipelin contribut
cystic
fibrosi patient one vertex
therapi drive
franchis sale
franchis maintain exclus
past earli
anoth vertex pipelin program
fewer cystic
fibrosi patient one vertex
therapi drive less
franchis sale
vertex face meaning competit
vertex leader treatment cystic fibrosi orkambi kalydeco standard
therapi cystic fibrosi patient homozyg mutat
rate residu function mutat vertex gener posit proof-of-concept
data multipl tripl combin regimen incorpor second gener corrector
patient tripl regimen appear
repres true breakthrough treatment improv qualiti life extend
life span cystic fibrosi world-wide moreov patent protect
least earli vertex franchis long commerci life early-stag
pipelin includ candid antitrypsin defici pain sickl cell diseas
follow posit chmp opinion receiv symkevi juli eu approv track
addit ph program adult near
complet vertex recent initi studi children age support eventu
label expans initi phase ii studi once-daili potenti
support develop part once-daili tripl clinic hold
lift vertex crispr expect initi ph i/ii studi sickl cell diseas
first patient enrol eu ph i/ii b-thal
soon initi ph iib dose-rang studi inhibitor acut pain test
oral formul data proof concept studi small fiber neuropathi
expect earli clinic develop first small molecul corrector
antitrypsin defici expect begin end final
termin develop cethrin dsmb ph iib trial spinal cord
injuri recommend trial stop futil expect program
low estim model
vertex busi continu perform well even advanc tripl symdeko
launch pace deliv y/i revenu growth growth
healthi project y/i though somewhat slower absent reimburs
major new territori franc uk symdeko launch orkambi
eu begin matur nonetheless first tripl launch
investor wait long re-acceler tripl produc dramat
improv lung function like extend life expect rapidli
broadli adopt base promis tripl regimen project
revenu compound-annual-growth-rate ep compound-annual-growth-rate highest larg cap
biotech base prospect strong long-term growth remain top larg
cap pick dcf-base price target
vertex leader discoveri develop candid treat cystic
fibrosi vertex first cystic fibrosi commerci product kalydeco ivacaftor
cftr potenti compound kalydeco approv fda
januari patient gate mutat mutat
addit residu function mutat subsequ ad label
seri supplement approv estim kalydeco achiev
world-wide sale patient gate
defect partial loss function cftr mutat vertex also develop
regimen contain kalydeco cftr corrector lumacaftor tezacaftor
potenti address cf patient harbor least one allel
orkambi lumacaftor ivacaftor succeed two pivot trial june
approv juli symdeko tezacaftor ivacaftor
produc posit data two phase trial march fda approv
februari expect licensur follow europ expect
orkambi symdeko wide adopt cystic fibrosi patient
homozyg mutat world-wide improv potenc
orkambi symdeko homozygot effect patient
one copi allel vertex advanc second gener
corrector clinic develop act synergist lumacaftor
tezacaftor complet correct fold defect cftr
tripl combin contain tezacaftor ivacaftor four second
gener corrector produc impress phase ii proof-of-concept data
tripl regimen result mean absolut improv
percentag point percentag point patient four
tripl regimen well toler base proof-of-concept data vertex
move two once-daili second gener corrector
phase homozyg heterozyg patient initi result
pivot studi anticip vertex expect file fda approv
tripl regimen het min patient impli
launch tripl regimen appear repres true breakthrough treatment
improv qualiti life extend life span
patient cystic fibrosi world-wide moreov second gener
corrector patent protect least earli vertex franchis
long commerci life model assum cystic fibrosi
patient one vertex therapi drive franchis sale
dcf-base price target
result two pivot trial tripl combin tezacaftor ivacaftor
complet enrol pivot trial tripl combin regimen
ema approv symkevi
initi phase iib dose-rang studi oral bunionectomi surgeri
obtain addit ex-u reimburs orkambi homozygot patient
initi phase trial sickl cell diseas
possibl updat merck kgaa oncolog
possibl in-licens partnership extern pipelin asset
advanc addit next-gener corrector develop
advanc addit non-cf pipelin candid clinic
phase ii data inhibitor small fiber neuropathi
result pivot trial tripl combin regimen homozyg het
initi phase ii studi monotherapi cf patient gate mutat
partner releas phase data pimodivir influenza non-hospit patient
file fda approv first tripl regimen
partner releas phase data pimodivir influenza hospit patient
cowen compani
cowen compani
statesnumb patient diagnos patient penetr patient per patient patient gate gate penetr patient per patient patient gate mutat homozyg homozyg regimen penetr patient vertex per patient patient heterozyg heterozyg regimen penetr patient vertex per patient hetero patient vertex kalydeco orkambi/symdeko/tripl cystic fibrosi revenu patient diagnos patient penetr patient per patient gate gate penetr patient per patient patient gate homozyg regimen penetr patient vertex per patient heterozyg heterozyg regimen penetr patient vertex per patient hetero row patient vertex kalydeco orkambi/symdeko/tripl cystic fibrosi revenu kalydeco kalydeco orkambi orkambi/symdeko/tripl cystic fibrosi patient vertex cystic fibrosi cowen
cowen compani
fy dec except per symdeko tripl growth expensesroyalti payment royaltiescost good product develop ex gener administr ex base cost loss incom rate incom loss attribut non-controlling lncome exclud soe exclud soe expens net share share stock option expens cowen
cowen compani
fy dec except per cagrrevenu kalydeco symdeko tripl growth expensesroyalti good product develop ex gener administr ex cost incometot loss incom rate lncome exclud soe exclud soe expens net share cowen
cowen compani
financi year incivek cystic fibrosi payment tax asset unus tax free year growth ratetermin valu termin valu net per valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
vertex deriv great major revenu two relat product kalydeco
orkambi forecast sale franchis difficult outlook could
alter new safety/efficaci find emerg competit alter medic
treatment paradigm chang pricing/reimburs environ vertex
stock price could also affect chang outlook key pipelin program
includ second gener corrector evalu market potenti
drug yet approv particularli riski
